Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Research Library

GLP-2 TIRZ research

6 articles to explore, with links to 9 original sources.

About GLP-2 TIRZ

TIRZ is the catalog name for tirzepatide, a peptide investigated at GIP and GLP-1 receptors.

Understand the science

  • Which two receptors recognize tirzepatide?

    Tirzepatide is designed to activate the receptors for glucose-dependent insulinotropic polypeptide, called GIP, and glucagon-like peptide-1, called GLP-1. The “GLP-2” part of the catalog label refers to the label alone.

    1 source (2022)

Explore study findings

  • What a 2026 analysis found across sleep apnea subgroups

    Tirzepatide is a modified peptide that activates the GIP and GLP-1 receptors. “GLP-2 TIRZ” is the catalog label. Tirzepatide’s tested targets are GIP and GLP-1, distinct from the GLP-2 receptor. A 2026 analysis asked how sleep apnea outcomes varied with participants’ starting characteristics.

    3 sources (2022–2026)

  • What a head-to-head trial taught researchers about glucose categories

    Tirzepatide is a peptide that activates GIP and GLP-1 receptors. It appears under “GLP-2 TIRZ” in the catalog, a name distinct from its receptor targets.

    3 sources (2022–2026)

Check methods and identity

  • What an antibody add-on study measured besides weight

    Tirzepatide is a peptide that activates GIP and GLP-1 receptors. The “GLP-2” wording in the catalog label does not correspond to a receptor target.

    2 sources (2022, 2026)

  • How SURMOUNT-MAINTAIN tested weight maintenance

    Tirzepatide activates GIP and GLP-1 receptors. In “GLP-2 TIRZ,” the GLP-2 wording is a catalog identifier. The SURMOUNT-MAINTAIN trial examined what happened to body weight after adults had already taken tirzepatide during an initial weight-loss phase.

    2 sources (2022, 2026)

Interpret the evidence

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice.